Alkermes reported early randomized Phase 1 data for ALKS 7290, an orexin agonist, in adults with ADHD. The company said the drug was well tolerated and that results showed a signal of efficacy based on changes on the Adult ADHD Investigator Symptom Rating Scale. With participants starting at a median score indicating moderate to severe symptoms, Alkermes reported a larger symptom score reduction in the higher-dose group after two weeks. The company framed this as the first dataset suggesting orexin agonists may extend beyond sleep-focused indications into ADHD. For ADHD development, the early readout keeps attention on whether this mechanism class can compete with existing treatment paradigms and whether longer studies can confirm both tolerability and clinical effect size.